Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

NCCN Task Force Report: Bone Health in Cancer Care.

Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH.

J Natl Compr Canc Netw. 2009 Jun;7 Suppl 3:S1-32; quiz S33-5.

2.

New generation of bisphosphonates: broad clinical utility in breast and prostate cancer.

Rosen LS.

Oncology (Williston Park). 2004 May;18(5 Suppl 3):26-32. Review.

PMID:
15202585
3.

[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].

Kudlacek S, Puntus T.

Wien Med Wochenschr. 2012 Sep;162(17-18):380-5. doi: 10.1007/s10354-012-0106-z. Epub 2012 Aug 9. Review. German.

PMID:
22875632
4.

Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.

Saylor PJ.

Asian J Androl. 2014 May-Jun;16(3):341-7. doi: 10.4103/1008-682X.122591. Review.

5.

Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer.

McKay RR, Taplin ME, Choueiri TK.

Hematol Oncol Clin North Am. 2013 Dec;27(6):1261-83, ix. doi: 10.1016/j.hoc.2013.08.009. Epub 2013 Sep 20. Review.

6.

Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.

[No authors listed]

J Support Oncol. 2006 Feb;4(2):99-100. No abstract available.

PMID:
16499137
7.

Prevention and treatment of bone loss in patients with nonmetastatic breast or prostate cancer who receive hormonal ablation therapy.

Limburg C, Maxwell C, Mautner B.

Clin J Oncol Nurs. 2014 Apr;18(2):223-30. doi: 10.1188/14.CJON.223-230.

PMID:
24675258
8.

Preservation of bone health in prostate cancer.

Lattouf JB, Saad F.

Curr Opin Support Palliat Care. 2007 Oct;1(3):192-7. doi: 10.1097/SPC.0b013e3282f0c74f. Review.

PMID:
18685362
9.

NCCN Task Force Report: Bone Health In Cancer Care.

Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, Litsas G, McKay R, Podoloff DA, Srinivas S, Van Poznak CH.

J Natl Compr Canc Netw. 2013 Aug;11 Suppl 3:S1-50; quiz S51. Review.

PMID:
23997241
10.

The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer.

Candelaria-Quintana D, Dayao ZR, Royce ME.

Breast Cancer Res Treat. 2012 Apr;132(2):355-63. doi: 10.1007/s10549-011-1800-z. Epub 2011 Oct 11. Review.

PMID:
21987034
11.

Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.

Saad F, Sternberg CN.

Nat Clin Pract Urol. 2007 Feb;4 Suppl 1:S3-13. Review.

PMID:
17264863
13.

The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.

Smith MR.

Oncology (Williston Park). 2004 May;18(5 Suppl 3):21-5. Review.

PMID:
15202584
14.

NCCN Task Force Report: Bone Health and Cancer Care.

Theriault RL, Biermann JS, Brown E, Brufsky A, Demers L, Grewal RK, Guise T, Jackson R, McEnery K, Podoloff D, Ravdin P, Shapiro CL, Smith M, Van Poznak CH.

J Natl Compr Canc Netw. 2006 May;4 Suppl 2:S1-20; quiz S21-2.

PMID:
16737674
15.

Metastasis and bone loss: advancing treatment and prevention.

Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Cl├ęzardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ.

Cancer Treat Rev. 2010 Dec;36(8):615-20. doi: 10.1016/j.ctrv.2010.04.003. Epub 2010 May 15. Review.

16.

[Bone and Men's Health. Bisphosphonate therapy for prostate cancer].

Suzuki H, Kamiya N, Yano M, Endo T, Takano M, Kawamura K, Imamoto T, Ichikawa T.

Clin Calcium. 2010 Feb;20(2):258-66. doi: CliCa1002258266. Review. Japanese.

PMID:
20118519
17.

[Bone targeting agents: bisphosphonates].

Debiais F.

Bull Cancer. 2013 Nov;100(11):1199-206. doi: 10.1684/bdc.2013.1840. Review. French.

PMID:
24158668
18.

Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer.

Michaud LB.

Am J Health Syst Pharm. 2010 Apr;67(7 Suppl 3):S20-30; quiz S31-3. doi: 10.2146/ajhp100078.

PMID:
20332495
19.

Treatment options for breast cancer and bone metastases.

Pecherstorfer M.

Womens Health (Lond). 2009 Mar;5(2):149-63. doi: 10.2217/17455057.5.2.149. Review.

PMID:
19245353
20.

Annual zoledronic acid: is less more?

Higano CS.

J Clin Oncol. 2007 Mar 20;25(9):1026. No abstract available.

PMID:
17369565

Supplemental Content

Support Center